Consumer News Eli Lilly Says Its New Diabetes Drug Was 94 Effective In Clinical Trials

Eli Lilly's next-generation obesity drug secures first phase III win

Shares of Eli Lilly LLY rose nearly 2% on Thursday after the company announced that a late-stage study evaluating its experimental once-weekly weight-loss drug, retatrutide, met all primary and key ... Read More

Major weight loss, pain relief seen with Eli Lilly's next-gen drug in late-stage trial

Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of their body weight while reducing osteoarthritis pain. Read More

Major Weight Loss and Knee-Pain Relief Seen With New Eli Lilly Drug

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug. Read More

Eli Lilly Reports Dramatic Weight Loss in Next-Gen Obesity-Drug Trial

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in a late-stage trial. Read More

Eli Lilly says its next generation weight loss drug has shown promise in early trials

Eli Lilly's next generation of weight loss drugs appear to show promise, possibly leading to even faster weight loss and added health benefits, early trial results suggest. The pharmaceutical company ... Read More

Eli Lilly's next generation weight loss drug shows promise, early trial results suggest

Early results showed that patients lost up to 20.1% of their body weight. Eli Lilly's next generation of weight loss drugs appear to show promise, possibly leading to even faster weight loss and added ... Read More

Eli Lilly’s weight loss and diabetes drug tops Keytruda as world’s best-selling medicine

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Merck, which has claimed ... Read More

Zepbound Maker Eli Lilly Reports Patients Achieved Dramatic Weight Loss in Study of Newest Obesity Drug

Some patients dropped out of the trial early because they had lost so much weight. Read More

Eli Lilly Says Weight-Loss Pill a Candidate for Speedy Approval Under New US Program

(Reuters) -Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's new national priority voucher, suggesting it is a strong candidate ... Read More

Eli Lilly's Weight-Loss Drugs Drove Its Stock Higher This Year. A New Plant in Alabama Could Boost Production

Eli Lilly said it plans to invest more than $6 billion in a new facility in Alabama to produce its experimental weight-loss pill. Read More